CN112098171B - Preparation method of urine chemical analysis quality control product - Google Patents
Preparation method of urine chemical analysis quality control product Download PDFInfo
- Publication number
- CN112098171B CN112098171B CN202010986899.4A CN202010986899A CN112098171B CN 112098171 B CN112098171 B CN 112098171B CN 202010986899 A CN202010986899 A CN 202010986899A CN 112098171 B CN112098171 B CN 112098171B
- Authority
- CN
- China
- Prior art keywords
- substitute
- urine
- quality control
- stirring
- solution prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002700 urine Anatomy 0.000 title claims abstract description 66
- 238000003908 quality control method Methods 0.000 title claims abstract description 64
- 239000000126 substance Substances 0.000 title claims abstract description 37
- 238000004458 analytical method Methods 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims abstract description 32
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 claims abstract description 30
- 150000002576 ketones Chemical class 0.000 claims abstract description 29
- 238000003756 stirring Methods 0.000 claims abstract description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 20
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 16
- 108010088751 Albumins Proteins 0.000 claims abstract description 15
- 102000009027 Albumins Human genes 0.000 claims abstract description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 13
- 239000008103 glucose Substances 0.000 claims abstract description 13
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 claims abstract description 12
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims abstract description 12
- 235000019796 monopotassium phosphate Nutrition 0.000 claims abstract description 12
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003755 preservative agent Substances 0.000 claims abstract description 10
- 239000011780 sodium chloride Substances 0.000 claims abstract description 10
- 235000010288 sodium nitrite Nutrition 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 8
- AXMKEYXDFDKKIO-UHFFFAOYSA-N bilane Chemical compound C=1C=C(CC=2NC(CC=3NC=CC=3)=CC=2)NC=1CC1=CC=CN1 AXMKEYXDFDKKIO-UHFFFAOYSA-N 0.000 claims abstract description 7
- 102000001554 Hemoglobins Human genes 0.000 claims description 7
- 108010054147 Hemoglobins Proteins 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- 229940098773 bovine serum albumin Drugs 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 210000000265 leukocyte Anatomy 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- XBPJVSRTTKVMEN-UHFFFAOYSA-N 2,4-dimethyl-1h-pyrrole-3-carboxylic acid Chemical compound CC1=CNC(C)=C1C(O)=O XBPJVSRTTKVMEN-UHFFFAOYSA-N 0.000 claims description 5
- MDWJZBVEVLTXDE-UHFFFAOYSA-N 2-methyl-1h-indol-5-ol Chemical compound OC1=CC=C2NC(C)=CC2=C1 MDWJZBVEVLTXDE-UHFFFAOYSA-N 0.000 claims description 5
- JDPRRECMRPCSIF-UHFFFAOYSA-N ethyl 3-oxobutanoate;sodium Chemical compound [Na].CCOC(=O)CC(C)=O JDPRRECMRPCSIF-UHFFFAOYSA-N 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 claims description 4
- 239000003633 blood substitute Substances 0.000 claims description 4
- LGAFIBCWNKPENX-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrrole-2,4-dicarboxylic acid Chemical compound CC=1NC(C(O)=O)=C(C)C=1C(O)=O LGAFIBCWNKPENX-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 2
- 108090000371 Esterases Proteins 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- -1 leukocyte substitute Chemical compound 0.000 claims description 2
- 229940040102 levulinic acid Drugs 0.000 claims description 2
- 229940058349 sodium levulinate Drugs 0.000 claims description 2
- AGCGGNCZCFZBNN-UHFFFAOYSA-M sodium;2-methyl-3-oxobutanoate Chemical compound [Na+].CC(=O)C(C)C([O-])=O AGCGGNCZCFZBNN-UHFFFAOYSA-M 0.000 claims description 2
- RDKYCKDVIYTSAJ-UHFFFAOYSA-M sodium;4-oxopentanoate Chemical compound [Na+].CC(=O)CCC([O-])=O RDKYCKDVIYTSAJ-UHFFFAOYSA-M 0.000 claims description 2
- IPBNQYLKHUNLQE-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid;azane Chemical group [NH4+].C=12C(S(=O)(=O)[O-])=CC=CC2=CC=CC=1NC1=CC=CC=C1 IPBNQYLKHUNLQE-UHFFFAOYSA-N 0.000 claims 1
- WCOATMADISNSBV-UHFFFAOYSA-K diacetyloxyalumanyl acetate Chemical compound [Al+3].CC([O-])=O.CC([O-])=O.CC([O-])=O WCOATMADISNSBV-UHFFFAOYSA-K 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 16
- 238000004090 dissolution Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 230000006872 improvement Effects 0.000 abstract description 5
- 238000005353 urine analysis Methods 0.000 abstract description 4
- 239000000337 buffer salt Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 36
- 238000012360 testing method Methods 0.000 description 21
- 238000011835 investigation Methods 0.000 description 18
- 238000011156 evaluation Methods 0.000 description 16
- 230000000007 visual effect Effects 0.000 description 10
- 239000002994 raw material Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 7
- 238000010257 thawing Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000013112 stability test Methods 0.000 description 5
- 108090001060 Lipase Proteins 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- XDILZEPJCPEDLT-UHFFFAOYSA-N [Na].[O-][N+]1=CC=CC=C1S Chemical compound [Na].[O-][N+]1=CC=CC=C1S XDILZEPJCPEDLT-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- PZPFXRQPPDCUQY-LNKPDPKZSA-M sodium;(z)-4-methoxy-4-oxobut-2-en-2-olate Chemical compound [Na+].COC(=O)\C=C(\C)[O-] PZPFXRQPPDCUQY-LNKPDPKZSA-M 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/38—Diluting, dispersing or mixing samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to the field of urine analysis and detection, in particular to a preparation method of a urine chemical analysis quality control product. Comprising the following steps: (1) Adding disodium hydrogen phosphate dodecahydrate into water, stirring and dissolving; (2) Adding a ketone body substitute into the solution prepared in the step (1), and stirring for dissolution; (3) Adding a urine bilinogen substitute into the solution prepared in the step (2), and stirring for dissolution; (4) Sequentially adding sodium chloride, a leucocyte substitute and potassium dihydrogen phosphate into the solution prepared in the step (3), and stirring for dissolution; (5) Sequentially adding bilirubin substitutes, sodium nitrite, glucose, red blood cell substitutes, albumin substitutes and preservatives into the solution prepared in the step (4), and stirring for dissolution. The addition sequence and the use amount of the buffer salt in the method have obvious improvement effect on the stability of the ketone body. The addition sequence of ketone bodies and urobilinogen, the dissolution pH and the dissolution time control have obvious improvement effect on the stability of the ketone bodies and the urobilinogen and the stability of other detection indexes.
Description
Technical Field
The invention relates to the field of urine analysis and detection, in particular to a preparation method of a urine chemical analysis quality control product.
Background
Urine routine is used as one of three routine examination, is not only the first choice and absolute necessity of diagnosis and curative effect observation of urinary system diseases, but also is helpful for diagnosis and treatment of other system diseases which can cause the change of biochemical components of blood. Urine chemical analysis project inter-room quality evaluation activities are carried out by all levels of temporary examination centers each year. The urine chemical analysis quality control product is used for quality control of a urine analyzer and a urine analysis test strip. The quality control can be performed on the detection of pH, albumin, glucose, ketone body, blood, nitrite, bilirubin, urobilinogen, leucocyte and specific gravity items. Compared with blood and biochemical tests, the urine analysis quality control difficulty is high, besides the method is not standardized, the steps of collecting, transporting and storing urine specimens are more, the control is difficult, the sensitivity and the fixed value standard of test strips and analyzers of various manufacturers are different, and the test strips and the analyzers can be monitored relatively easily by using the quality control product.
Cui Yunlong (preparation of urine quality control substance and clinical preliminary application experience. Shanxi J.medicine, 1986, 15 (3): 185) the urine quality control substance is prepared by taking normal human urine as a basic matrix solution, so that the matrix effect is eliminated to a certain extent, but a large amount of normal human urine with stable quality is difficult to obtain, and meanwhile, the urine of normal human is different due to the difference of individual living habits, so that the batch-to-batch difference of the quality control substance is larger. The use of a large amount of urine can pollute the environment, and the treatment of pathological urine can also pose a threat to the health of operators. The urine is high in treatment and preservation cost. These are drawbacks of such techniques.
Before using, a certain amount of water is needed to dissolve the freeze-dried powder quality control product, and then the freeze-dried powder quality control product is poured into a container for use. Such quality control is inconvenient to use and is prone to causing operational errors. The liquid is dissolved into the liquid and then needs to be used in time, so that the liquid is unstable and can not be stored, and waste is caused.
In order to avoid the problems of difficult quality control, environmental pollution and the like caused by adopting urine as a basic matrix liquid to prepare the urine quality control product. The prior art also commonly adopts chemical raw materials as substitutes for various detection indexes of urine to prepare urine quality control products. For example, chinese patent publication No. CN106771112A discloses a multi-item composite urine quality control liquid. Acetone, ethyl acetoacetate and the like are used as ketone body substitutes, direct bilirubin, 1-naphthalene sulfonate and the like are used as bilirubin substitutes, indole, pyrrole and derivatives thereof are used as urine bilinogen substitutes, and a plurality of composite urine quality control liquids are prepared. However, because more organic chemical raw materials are adopted, in order to solve the problems of raw material solubility and product stability, the product is added with cosolvent and stabilizer such as tween, poloxamer and the like, so that the cost is increased, the stability is not ideal, meanwhile, the use of 2-mercaptopyridine oxide sodium salt can cause false positive of ketone bodies and also can interfere with the detection of hemoglobin. In the preparation of urine quality control products in documents and patents, cosolvents such as surfactants and stabilizers or use are often used in consideration of the problems of raw material solubility and product stability.
Disclosure of Invention
In view of the above, the invention provides a preparation method of a urine chemical analysis quality control product. The preparation method has obvious improvement effect on ketone body and urinary cholesterin stability and other detection index stability through the control of specific raw material addition sequence and use amount, dissolution pH and dissolution time.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a preparation method of a urine chemical analysis quality control product, which comprises the following steps: buffer pair, ketone body substitute, urine bilinogen substitute, sodium chloride, leukocyte substitute, bilirubin substitute, sodium nitrite, glucose, erythrocyte substitute, albumin substitute, preservative and water;
the ketone body substitute is one or more of acetylsalicylic acid, sodium levulinate, levulinic acid, ethyl acetoacetate sodium salt, methyl acetoacetate sodium salt and aluminum triacetylacetonate;
the urobilinogen substitute is one or more of 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid, 2, 4-dimethyl pyrrole-3, 5-dicarboxylic acid, N-methyl pyrrolidone and 5-hydroxy-2-methyl-indole;
the bilirubin substitute is 8-phenylaminonaphthalene-1-ammonium sulfonate;
the buffer pair consists of disodium hydrogen phosphate dodecahydrate and potassium dihydrogen phosphate;
the preparation method comprises the following steps:
(1) Adding disodium hydrogen phosphate dodecahydrate into water, stirring and dissolving;
(2) Adding the ketone body substitute into the solution prepared in the step (1), and stirring and dissolving for 10-30 minutes;
(3) Adding a urine bilinogen substitute into the solution prepared in the step (2), and stirring and dissolving for 5-20 minutes;
(4) Sequentially adding sodium chloride, a leucocyte substitute and potassium dihydrogen phosphate into the solution prepared in the step (3), and stirring and dissolving for 5-15 minutes;
(5) Sequentially adding bilirubin substitutes, sodium nitrite, glucose, red blood cell substitutes, albumin substitutes and preservatives into the solution prepared in the step (4), and stirring and dissolving for 15-50 minutes.
The research of the application finds that the urine chemical analysis quality control product is not only related to the screening of the preparation raw materials, but also has important influence on the stability and quality control accuracy of the product by the preparation process of the urine quality control liquid.
Preferably, the concentration of each component in the quality control product is as follows:
preferably, the leukocyte substitute is an esterase.
Preferably, the red blood cell substitute is bovine hemoglobin.
Preferably, the albumin substitute is bovine serum albumin.
Preferably, the preservative is Proclin 300.
Preferably, the pH value of the urine chemical analysis quality control product is 6.0-8.5.
Preferably, the pH value of the solution prepared in the step (2) is 9.5-11.5.
Preferably, the pH value of the solution prepared in the step (3) is 8.5-10.0.
Preferably, the pH value of the solution prepared in the step (4) is 6.5-8.5.
The invention provides a preparation method of a urine chemical analysis quality control product. The preparation method comprises the following steps: (1) Adding disodium hydrogen phosphate dodecahydrate into water, stirring and dissolving; (2) Adding the ketone body substitute into the solution prepared in the step (1), and stirring and dissolving for 10-30 minutes; (3) Adding a urine bilinogen substitute into the solution prepared in the step (2), and stirring and dissolving for 5-20 minutes; (4) Sequentially adding sodium chloride, a leucocyte substitute and potassium dihydrogen phosphate into the solution prepared in the step (3), and stirring and dissolving for 5-15 minutes; (5) Sequentially adding bilirubin substitutes, sodium nitrite, glucose, red blood cell substitutes, albumin substitutes and preservatives into the solution prepared in the step (4), and stirring and dissolving for 15-50 minutes. By adopting the technical scheme, compared with the prior art, the invention has the following technical effects:
the urine chemical analysis quality control product and the preparation method thereof provided by the invention do not use organic solvents, auxiliary agents and stabilizers, and have the advantages of small pollution, low cost, simple process and good product stability. The invention considers the influence of raw material screening on the performance such as cost, product stability and the like, and fully examines the influence of process control on the product performance. For example, the addition sequence and the use amount of the phosphate have obvious improvement effect on the stability of the ketone body. The addition sequence of ketone bodies and urobilinogen, the dissolution pH and the dissolution time control have obvious improvement effect on the stability of the ketone bodies and the urobilinogen and the stability of other detection indexes.
Detailed Description
The invention discloses a preparation method of a urine chemical analysis quality control product, and a person skilled in the art can properly improve the process parameters by referring to the content of the invention. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included in the present invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that variations and modifications can be made in the methods and applications described herein, and in the practice and application of the techniques of this invention, without departing from the spirit or scope of the invention.
The raw materials used in the preparation method of the urine chemical analysis quality control product provided by the invention can be purchased from the market.
The invention is further illustrated by the following examples:
example 1
The embodiment provides a urine chemical analysis quality control article, which comprises:
(1) Disodium phosphate dodecahydrate: 25g/L;
(2) Potassium dihydrogen phosphate: 6g/L;
(3) Ketone body substitute: 15g/L;
(4) Replacement of urobilinogen: 1.2g/L;
(5) Sodium chloride: 5g/L;
(6) Leukocyte replacement: 0.2g/L;
(7) Bilirubin substitutes: 0.1g/L;
(8) Sodium nitrite: 25mg/L;
(9) Glucose: 5g/L;
(10) Erythrocyte substitute: 0.05g/L;
(11) Albumin substitute: 6g/L;
(12) Preservative Proclin 300:0.5g/L;
wherein the buffer pair is a phosphate buffer pair, and the phosphate buffer pair is disodium hydrogen phosphate dodecahydrate and potassium dihydrogen phosphate; the ketone body substitute is ethyl acetoacetate sodium salt; the urobilinogen substitute is 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid; the leucocyte substitute is lipase; the bilirubin substitute is 8-anilinonaphthalene-1-ammonium sulfonate; the red blood cell substitute is bovine hemoglobin; the albumin substitute is bovine serum albumin; the pH value of the urine chemical analysis quality control product is 6.5-7.5.
The preparation method comprises the following steps:
25g of disodium hydrogen phosphate dodecahydrate was added to 1L of purified water and stirred to dissolve it sufficiently. 15g of ethyl acetoacetate sodium salt was added to the solution and stirred for 30 minutes, and the pH of the solution was controlled to be in the range of 9.5 to 9.8.
Adding 1.2g of 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid into the solution, stirring for 20 minutes to fully dissolve the 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid, wherein the pH value of the solution is 8.5-9.0; 5g of sodium chloride, 0.2g of lipase and 6g of monopotassium phosphate are sequentially added into the solution while stirring, and the solution is stirred for 30 minutes to be fully dissolved, wherein the pH value of the solution is 8.0-8.5.
And (3) adding 0.1g of 8-phenylaminonaphthalene-1-ammonium sulfonate, 25mg of sodium nitrite, 5g of glucose dosage, 0.05g of bovine hemoglobin, 6g of bovine serum albumin and 0.5g of Proclin300 into the solution while stirring, and stirring for 30 minutes to fully dissolve to obtain the required urine chemical analysis quality control solution, wherein the pH value of the prepared solution is 6.5-7.5.
Stability verification test:
the prepared solution is subjected to uniformity, unsealing stability at 2-8 ℃, accelerating stability at 37 ℃, simulated transportation stability, serial stability, freeze thawing stability, room temperature stability and real-time stability after transportation, and the results are as follows:
uniformity investigation: taking 10 bottles of the urine chemical analysis quality control product prepared in the example 1, detecting the quality control product for 1 time, wherein the consistency degree of detection results of specific gravity, pH, albumin, glucose, ketone body, blood, nitrite, bilirubin, urobilinogen and leucocytes and the nominal value is 100%. The results are detailed in Table 1:
table 1 results of homogeneity investigation
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
2-8deg.C unsealing stability investigation: taking 3 bottles of the urine chemical analysis quality control product prepared in the embodiment 1, unsealing, sealing and storing at 2-8 ℃ in a dark place, checking for 7 days, 14 days, 21 days and 28 days respectively, detecting 1 time per bottle, and detecting each visual measurement value, wherein the results are all within a given range. The results are detailed in Table 2:
table 2 results of examining the opening stability
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
Accelerated stability investigation at 37℃: taking 3 bottles of the urine chemical analysis quality control product prepared in the example 1, and checking for 3 days, 7 days, 10 days and 14 days respectively at 37 ℃ for 1 time per bottle; the results of the accelerated failure 14 at 37℃are also within the range of nominal values, and are shown in Table 3.
TABLE 3 results of accelerated stability studies at 37℃
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
Transportation stability investigation: taking 3 bottles of the quality control product prepared in the embodiment 1, simulating vehicle-mounted transportation in 37 ℃ environment, checking for 3 days, 7 days, 10 days and 14 days respectively, detecting 1 time per bottle, and detecting various visual determination values, wherein the results are all in a given range. The results are detailed in Table 4.
Table 4 transport stability test results
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
Series stability investigation: taking 3 bottles of the urine chemical analysis quality control product prepared in the embodiment 1, respectively simulating vehicle-mounted examination for 3 days, 7 days, 10 days and 14 days in a 37 ℃ environment, unsealing, sealing and storing in a dark place at 2-8 ℃ for 14 days, and detecting for 1 time in each bottle, wherein all visual examination fixed values meet the requirements. The results are detailed in Table 5.
Table 5 series stability test results
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
Freeze thawing stability investigation: taking 3 bottles of the urine quality control product prepared in the example 1, respectively checking freezing and thawing for 3 times, 7 times and 10 times under the environment of-20 ℃, detecting 1 time for each bottle, and detecting each visual measurement value, wherein the detection results are all in a given range. The results are detailed in Table 6.
TABLE 6 freeze-thaw stability investigation results
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
Room temperature stability study: taking 3 bottles of the urine quality control product prepared in the example 1, and checking for 3 days, 7 days, 14 days, 21 days and 28 days respectively at room temperature and 25 ℃ for 1 time, wherein the detection results are all in a given range. The results are detailed in Table 7.
Table 7 examination of room temperature stability
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
Real-time stability inspection after transportation: taking 3 bottles of the urine quality control product prepared in the embodiment 1, immediately detecting after 7 days of simulated vehicle transportation, storing in 4 th month, 8 th month, 12 th month and 18 th month after transportation at the temperature of 2-8 ℃, detecting 1 time per bottle, and detecting each visual fixed value, wherein the detection results are all in a given range. The results are detailed in Table 8.
Table 8 real-time stability after shipping
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
From the stability investigation result, the urine chemical analysis quality control level prepared in the example 1 has good stability.
Example 2
The embodiment provides a urine chemical analysis quality control article, which comprises:
(1) Disodium phosphate dodecahydrate: 5g/L;
(2) Potassium dihydrogen phosphate: 0.7g/L;
(3) Ketone body substitute: 3g/L;
(4) Replacement of urobilinogen: 0.2g/L;
(5) Sodium chloride: 15g/L;
(6) Leukocyte replacement: 1g/L;
(7) Bilirubin substitutes: 1g/L;
(8) Sodium nitrite: 10mg/L;
(9) Glucose: 20g/L;
(10) Erythrocyte substitute: 1g/L;
(11) Albumin substitute: 1g/L;
(12) Preservative Proclin 300:5g/L;
wherein the buffer pair is a phosphate buffer pair, and the phosphate buffer pair is disodium hydrogen phosphate dodecahydrate and potassium dihydrogen phosphate; the ketone body substitute is ethyl acetoacetate sodium salt; the urobilinogen substitute is 5-hydroxy-2-methyl-indole; the leucocyte substitute is lipase; the bilirubin substitute is 8-anilinonaphthalene-1-ammonium sulfonate; the red blood cell substitute is bovine hemoglobin; the albumin substitute is bovine serum albumin; the pH value of the urine chemical analysis quality control product is 7.5-8.5.
The preparation method comprises the following steps:
5g of disodium hydrogen phosphate dodecahydrate was added to 1L of purified water and stirred to be sufficiently dissolved. 3g of sodium methyl acetoacetate was added to the solution and stirred for 10 minutes, and the pH of the solution was controlled to be in the range of 10.8 to 11.5.
Adding 0.2g of 5-hydroxy-2-methyl-indole into the solution, stirring for 5 minutes to fully dissolve the 5-hydroxy-2-methyl-indole, wherein the pH value of the solution is 9.5-10.0;
15g of sodium chloride, 1g of lipase and 0.7g of monopotassium phosphate are sequentially added into the solution while stirring, and the solution is stirred for 5 minutes to be fully dissolved, wherein the pH value of the solution is 6.5-7.0.
1g of 8-phenylaminonaphthalene-1-ammonium sulfonate, 10mg of sodium nitrite, 20g of glucose dosage, 1g of bovine hemoglobin, 1g of bovine serum albumin and 5g of Proclin300 are sequentially added into the solution while stirring, and the solution is stirred for 15 minutes to be fully dissolved, so that the required urine chemical analysis quality control solution is obtained, and the pH value of the prepared solution is 7.5-8.5.
Stability verification test:
the prepared solution is subjected to uniformity, unsealing stability at 2-8 ℃, accelerating stability at 37 ℃, simulated transportation stability, serial stability, freeze thawing stability, room temperature stability and real-time stability after transportation, and the results are as follows:
uniformity investigation: taking 10 bottles of the urine chemical analysis quality control product prepared in the example 2, wherein each bottle of the quality control product is detected for 1 time, and the consistency degree of detection results of specific gravity, pH, albumin, glucose, ketone bodies, blood, nitrite, bilirubin, urobilinogen and leucocytes and the nominal values is 100 percent. The results are detailed in Table 9.
Table 9 results of uniformity investigation
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
2-8deg.C unsealing stability investigation: taking 3 bottles of the urine chemical analysis quality control product prepared in the embodiment 2, unsealing, sealing and storing at 2-8 ℃ in a dark place, checking for 7 days, 14 days, 21 days and 28 days respectively, detecting 1 time per bottle, and detecting each visual measurement value, wherein the results are all within a given range. The results are detailed in Table 10.
Table 10 results of examination of opening stability
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
Accelerated stability investigation at 37℃: taking 3 bottles of the urine chemical analysis quality control product prepared in the example 2, and checking for 3 days, 7 days, 10 days and 14 days respectively at 37 ℃ for 1 time per bottle; the results of the accelerated failure 14 at 37℃are also within the range of the nominal values, and the results are shown in Table 11.
Table 11 results of accelerated stability test at 37 ℃
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
Transportation stability investigation: taking 3 bottles of the quality control product prepared in the embodiment 2, simulating vehicle-mounted transportation in 37 ℃ environment, checking for 3 days, 7 days, 10 days and 14 days respectively, detecting 1 time per bottle, and detecting various visual determination values, wherein the results are all in a given range. The results are detailed in Table 12.
Table 12 transport stability test results
/>
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
Series stability investigation: taking 3 bottles of the urine chemical analysis quality control product prepared in the embodiment 2, respectively simulating vehicle-mounted examination for 3 days, 7 days, 10 days and 14 days in a 37 ℃ environment, unsealing, sealing and storing in a dark place at 2-8 ℃ for 14 days, and detecting 1 time per bottle, wherein all visual examination fixed values meet the requirements. The results are detailed in Table 13.
TABLE 13 series stability test results
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
Freeze thawing stability investigation: taking 3 bottles of the urine quality control product prepared in the example 2, respectively checking freezing and thawing for 3 times, 7 times and 10 times under the environment of-20 ℃, detecting 1 time for each bottle, and detecting each visual measurement value, wherein the detection results are all within a given range. The results are detailed in Table 14.
TABLE 14 freeze-thaw stability investigation results
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
Room temperature stability study: taking 3 bottles of the urine quality control product prepared in the example 2, and checking for 3 days, 7 days, 14 days, 21 days and 28 days respectively at room temperature and 25 ℃ for 1 time, wherein the detection results are all in a given range. The results are detailed in Table 15.
Table 15 examination of room temperature stability
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
Real-time stability inspection after transportation: taking 3 bottles of the urine quality control product prepared in the embodiment 2, immediately detecting after 7 days of simulated vehicle transportation, storing in 4 th month, 8 th month, 12 th month and 18 th month after transportation at the temperature of 2-8 ℃, detecting 1 time per bottle, and detecting each visual fixed value, wherein the detection results are all in a given range. The results are detailed in Table 16.
Table 16 real-time stability after shipping
Note that: the positive intensity range is evaluated by test paper strip evaluation standards of mainstream manufacturers, and the positive intensity is represented by the number of the positive intensity; + -indicates weak positives; -negative.
From the stability investigation result, the urine chemical analysis quality control product prepared in the example 2 has good stability.
Comparative example
In the technical development process, the applicant has conducted a great deal of research on screening of urine quality control index substitutes. Through screening the urine quality control index substitute raw materials, pollution hazard is reduced as much as possible, and technical cost is reduced. A great deal of research is also being conducted on the effect of the formulation process on the product performance. Taking example 1 as an example, if a ketone body substitute is added to an aqueous solution in the preparation process, the sensitivity of the ketone body is not high, the stability is extremely poor, and the signal value of the ketone body is reduced to be negative after the ketone body is placed for 1 day at normal temperature. In the preparation process of example 1, the dissolution and stirring time of ketone bodies is too short, the sensitivity is insufficient, and the stability is lowered when the stirring time is too long. For example, in the preparation process of example 2, if the buffer system is prepared first and then the urobilinogen substitute is added, the urobilinogen substitute is difficult to dissolve, the sensitivity is low, the appearance of the product is poor, and the stability is also obviously reduced.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (6)
1. A method for preparing a urine chemical analysis quality control product, which is characterized in that the quality control product comprises: buffer pair, ketone body substitute, urine bilinogen substitute, sodium chloride, leukocyte substitute, bilirubin substitute, sodium nitrite, glucose, erythrocyte substitute, albumin substitute, preservative and water;
the ketone body substitute is one or more of acetylsalicylic acid, sodium levulinate, levulinic acid, ethyl acetoacetate sodium salt, methyl acetoacetate sodium salt and aluminum triacetate;
the urobilinogen substitute is one or more of 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid, 2, 4-dimethyl pyrrole-3, 5-dicarboxylic acid, N-methyl pyrrolidone and 5-hydroxy-2-methyl-indole;
the bilirubin substitute is 8-anilinonaphthalene-1-sulfonic acid ammonium salt;
the buffer pair consists of disodium hydrogen phosphate dodecahydrate and potassium dihydrogen phosphate;
the preparation method comprises the following steps:
(1) Adding disodium hydrogen phosphate dodecahydrate into water, stirring and dissolving;
(2) Adding the ketone body substitute into the solution prepared in the step (1), and stirring and dissolving for 10-30 minutes;
(3) Adding a urine bilinogen substitute into the solution prepared in the step (2), and stirring and dissolving for 5-20 minutes;
(4) Sequentially adding sodium chloride, a leucocyte substitute and potassium dihydrogen phosphate into the solution prepared in the step (3), and stirring and dissolving for 5-15 minutes;
(5) Sequentially adding bilirubin substitutes, sodium nitrite, glucose, red blood cell substitutes, albumin substitutes and preservatives into the solution prepared in the step (4), and stirring and dissolving for 15-50 minutes;
the quality control product comprises the following components in concentration:
the pH value of the urine chemical analysis quality control product is 6.0-8.5.
2. The method of claim 1, wherein the leukocyte substitute is an esterase.
3. The method of claim 1, wherein the red blood cell substitute is bovine hemoglobin.
4. The method of claim 1, wherein the albumin substitute is bovine serum albumin.
5. The method of claim 1, wherein the preservative is Proclin 300.
6. The process according to any one of claims 1 to 5, wherein the solution prepared in step (2) has a pH of 9.5 to 11.5; the pH value of the solution prepared in the step (3) is 8.5-10.0; the pH value of the solution prepared in the step (4) is 6.5-8.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010986899.4A CN112098171B (en) | 2020-09-18 | 2020-09-18 | Preparation method of urine chemical analysis quality control product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010986899.4A CN112098171B (en) | 2020-09-18 | 2020-09-18 | Preparation method of urine chemical analysis quality control product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112098171A CN112098171A (en) | 2020-12-18 |
| CN112098171B true CN112098171B (en) | 2023-12-22 |
Family
ID=73759482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010986899.4A Active CN112098171B (en) | 2020-09-18 | 2020-09-18 | Preparation method of urine chemical analysis quality control product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112098171B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4298498A (en) * | 1978-12-21 | 1981-11-03 | Boehringer Mannheim Gmbh | Control reagent for test strips for determining urobilinogen in urine |
| US5278073A (en) * | 1991-05-08 | 1994-01-11 | Streck Laboratories, Inc. | Method of bilirubin assay |
| US5516700A (en) * | 1993-05-28 | 1996-05-14 | Chimera Research And Chemical, Inc. | Automated urinalysis method |
| CN1329250A (en) * | 2001-08-03 | 2002-01-02 | 长春市迪瑞检验制品有限责任公司 | Quality control liquor for analysis of urine and its preparation method |
| CN111638106A (en) * | 2020-06-09 | 2020-09-08 | 吉林基蛋生物科技有限公司 | Dry chemical analysis quality control substance for urine |
-
2020
- 2020-09-18 CN CN202010986899.4A patent/CN112098171B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4298498A (en) * | 1978-12-21 | 1981-11-03 | Boehringer Mannheim Gmbh | Control reagent for test strips for determining urobilinogen in urine |
| US5278073A (en) * | 1991-05-08 | 1994-01-11 | Streck Laboratories, Inc. | Method of bilirubin assay |
| US5516700A (en) * | 1993-05-28 | 1996-05-14 | Chimera Research And Chemical, Inc. | Automated urinalysis method |
| CN1329250A (en) * | 2001-08-03 | 2002-01-02 | 长春市迪瑞检验制品有限责任公司 | Quality control liquor for analysis of urine and its preparation method |
| CN111638106A (en) * | 2020-06-09 | 2020-09-08 | 吉林基蛋生物科技有限公司 | Dry chemical analysis quality control substance for urine |
Non-Patent Citations (1)
| Title |
|---|
| 人工尿液质控物的配制与应用;许凯声, 陈小华, 陈红兵, 肖于飞, 泮高辉;检验医学(第04期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112098171A (en) | 2020-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106771112B (en) | A kind of multinomial compound quality control liquor for analysis of urine | |
| CN111638106B (en) | Urine dry chemical analysis quality control object | |
| DE2633268C3 (en) | Blood gas control medium and method for making the same | |
| Whiting et al. | Serum and urine N-acetyl-β-D-glucosaminidase in diabetics on diagnosis and subsequent treatment, and stable insulin dependent diabetics | |
| DE1698180C3 (en) | Process for the production of a blood serum reference standard | |
| Nathan et al. | A colorimetric procedure for the determination of blood ammonia | |
| CN101672853B (en) | Blood cell analyzer calibrator and preparation process thereof | |
| CN112067398B (en) | Urine chemical analysis quality control product | |
| Witeska et al. | Disodium EDTA used as anticoagulant causes hemolysis in common carp blood | |
| CN107727869A (en) | Kit of antinuclear antibodies and preparation method thereof in a kind of measure serum | |
| Martinez-Subiela et al. | Comparison of two automated spectrophotometric methods for ceruloplasmin measurement in pigs | |
| CN111208220A (en) | Preparation and application of quality control substance of catecholamine substances and metabolites of plasma type freeze-dried powder | |
| CN105758700A (en) | Lyophilized whole blood controls for G6PD (glucose-6-phosphate dehydrogenase) and preparation method of lyophilized whole blood controls | |
| CN112098171B (en) | Preparation method of urine chemical analysis quality control product | |
| CN112067399B (en) | Preparation method of urine chemical analysis quality control product | |
| Hauet et al. | Citrate, acetate and renal medullary osmolyte excretion in urine as predictor of renal changes after cold ischaemia and transplantation | |
| WO2020010739A1 (en) | Mercury-free p-hydroxyl phenylalanine detection reagent and preparation method and application thereof | |
| WO2020010737A1 (en) | P-hydroxyphenylalanine test strip, preparation method and application | |
| JPS6047695A (en) | Simple method for determination of freshness-judgement constant k of fish and shellfish | |
| CN105021609A (en) | Ischemia-modified albumin detection reagent and detection method thereof | |
| Johnston et al. | Influence of biopsy specimen size, tissue fixation, and assay variation on copper, iron, and zinc concentrations in canine livers | |
| CN108956598B (en) | Microfluidic paper chip array and preparation method and application thereof | |
| CN109470533B (en) | Preparation method of human whole blood matrix quality control product for portable glucometer | |
| CN116429526A (en) | Urine chemical analysis quality control product and preparation method thereof | |
| CN105445467A (en) | Method for detecting bacterial endotoxin of sodium metabisulfite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |